id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-335233-m9vc994p	Kaushik, Ashlesha	COVID-19 Pandemic in India: What Lies Ahead-Letter to the Editor: Mitra P, Misra S, Sharma P. COVID-19 Pandemic in India: What Lies Ahead [published online ahead of print, 2020 Apr 20]. Indian J Clin Biochem. 2020;1–3. doi: https://doi.org/10.1007/s12291-020-00886-6	2020-06-10		.txt	text/plain	850	54	46	Older adults are most severely affected as noted by the authors; however, novel pediatric manifestations resembling Kawasaki disease have been recently recognized, marked by elevated biochemical markers of inflammation including ferritin and D-dimers [4] , labeled recently as Multisystem Inflammatory Syndrome by the World Health Organization. Therapy with convalescent plasma has shown promise and a Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 associated Complications in Moderate Disease (PLACID Trial) has been initiated by Indian Council of Medical Research (ICMR) in 46 hospitals within India [7] . Thus far, a total of 36, 11,599 patient-samples have been tested for COVID-19 in India [3] . Till now, COVID-19 in India has been addressed predominantly by containment measures (quarantine, isolation of infected individuals, contact-tracing and reducing movement of people in areas with high case-loads). COVID-19 Pandemic in India: What lies ahead	./cache/cord-335233-m9vc994p.txt	./txt/cord-335233-m9vc994p.txt